CL2008000669A1 - Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras. - Google Patents
Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras.Info
- Publication number
- CL2008000669A1 CL2008000669A1 CL2008000669A CL2008000669A CL2008000669A1 CL 2008000669 A1 CL2008000669 A1 CL 2008000669A1 CL 2008000669 A CL2008000669 A CL 2008000669A CL 2008000669 A CL2008000669 A CL 2008000669A CL 2008000669 A1 CL2008000669 A1 CL 2008000669A1
- Authority
- CL
- Chile
- Prior art keywords
- thiazolidinediones
- alkylated
- cancer
- pharmaceutical composition
- metabolic syndrome
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000001145 Metabolic Syndrome Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001467 thiazolidinediones Chemical class 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89345807P | 2007-03-07 | 2007-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008000669A1 true CL2008000669A1 (es) | 2008-11-03 |
Family
ID=39720674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008000669A CL2008000669A1 (es) | 2007-03-07 | 2008-03-06 | Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8119669B2 (enExample) |
| EP (1) | EP2132188B1 (enExample) |
| JP (1) | JP2010520307A (enExample) |
| KR (1) | KR20090118103A (enExample) |
| CN (1) | CN101679326B (enExample) |
| AR (1) | AR065656A1 (enExample) |
| AT (1) | ATE537157T1 (enExample) |
| AU (1) | AU2008222749A1 (enExample) |
| BR (1) | BRPI0808662B8 (enExample) |
| CA (1) | CA2679965A1 (enExample) |
| CL (1) | CL2008000669A1 (enExample) |
| CY (1) | CY1112778T1 (enExample) |
| DK (1) | DK2132188T3 (enExample) |
| EA (1) | EA200970838A1 (enExample) |
| ES (1) | ES2377165T3 (enExample) |
| HR (1) | HRP20120160T1 (enExample) |
| IL (1) | IL200758A0 (enExample) |
| MX (1) | MX2009009519A (enExample) |
| NZ (1) | NZ579418A (enExample) |
| PL (1) | PL2132188T3 (enExample) |
| PT (1) | PT2132188E (enExample) |
| RS (1) | RS52247B (enExample) |
| SI (1) | SI2132188T1 (enExample) |
| TW (1) | TW200902507A (enExample) |
| WO (1) | WO2008109731A2 (enExample) |
| ZA (1) | ZA200906953B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| CN101679322A (zh) * | 2007-03-07 | 2010-03-24 | 詹森药业有限公司 | 用作雌激素相关性受体-α调节剂的取代苯氧基噻唑烷二酮类化合物 |
| BRPI0817101A2 (pt) | 2007-09-14 | 2017-05-09 | Addex Pharmaceuticals Sa | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas |
| DK2203439T3 (da) | 2007-09-14 | 2011-04-18 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituerede 4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']-bipyridinyl-2'-oner |
| KR20100080597A (ko) | 2007-09-14 | 2010-07-09 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된-４-페닐-1ｈ-피리딘-2-온 |
| MX2010005110A (es) | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
| EP2254576B1 (en) * | 2008-02-22 | 2013-08-28 | The Ohio State University Research Foundation | Androgen receptor-ablative agents |
| AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
| JO2907B1 (en) | 2009-05-12 | 2015-09-15 | اديكس فرما اس ايه | Pyridine derivatives 1, 2, 4 trisolo [4, 3-A] and their uses as positive LLs for 2MGLUR receptors |
| NZ596053A (en) | 2009-05-12 | 2013-05-31 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP2011057643A (ja) * | 2009-09-14 | 2011-03-24 | Sumitomo Chemical Co Ltd | ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物 |
| JP2011057644A (ja) * | 2009-09-14 | 2011-03-24 | Sumitomo Chemical Co Ltd | ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物 |
| EP2536717B1 (en) | 2010-02-17 | 2014-06-04 | Janssen Pharmaceutica, N.V. | Aminothiazolones as estrogen related receptor-alpha modulators |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| WO2012153775A1 (ja) * | 2011-05-10 | 2012-11-15 | 国立大学法人神戸大学 | Ras機能阻害作用を有するチオキソチアゾリジン誘導体 |
| WO2013018929A1 (en) | 2011-08-04 | 2013-02-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| US10660882B2 (en) | 2012-03-26 | 2020-05-26 | Nippon Chemiphar Co., Ltd. | Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma |
| WO2014060477A1 (en) * | 2012-10-17 | 2014-04-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating bone metastases in prostate cancer patients |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| EP3632428A1 (en) | 2013-09-25 | 2020-04-08 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for use in the prophylactic or therapeutic treatment of giant cell tumors occurring in bone and soft tissue or of chondrosarcoma |
| HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
| EA033889B1 (ru) | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) * | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| CN108366992A (zh) | 2015-11-02 | 2018-08-03 | 耶鲁大学 | 蛋白水解靶向嵌合体化合物及其制备和应用方法 |
| EP4316477A1 (en) * | 2018-08-22 | 2024-02-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods for treating cardiac valve disease |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| HK1043113A1 (zh) * | 1999-07-01 | 2002-09-06 | Geron Corporation | 端粒酶抑制劑及其使用方法 |
| JP2001072592A (ja) * | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| AU2001257022B2 (en) | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
| DE10131899A1 (de) | 2001-07-04 | 2003-02-27 | Boehringer Ingelheim Pharma | In vitro-Screening-Assay für gamma-Secretase |
| JP2006500399A (ja) * | 2002-04-30 | 2006-01-05 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネルブロッカーとしての、アリール−結合−アリール置換された、チアゾリジン−ジオンおよびオキサゾリジン−ジオン |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| WO2006004555A1 (en) | 2004-06-30 | 2006-01-12 | Paysetter Pte Ltd | System and method for facilitating transfer of physical money and/or credit |
| AU2005275279A1 (en) * | 2004-07-14 | 2006-02-23 | Janssen Pharmaceutica N.V. | Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases |
| JP4931824B2 (ja) | 2004-10-22 | 2012-05-16 | エグゼリクシス， インコーポレイテッド | 薬学的組成物 |
-
2008
- 2008-03-06 EP EP08731517A patent/EP2132188B1/en active Active
- 2008-03-06 NZ NZ579418A patent/NZ579418A/en not_active IP Right Cessation
- 2008-03-06 MX MX2009009519A patent/MX2009009519A/es active IP Right Grant
- 2008-03-06 PT PT08731517T patent/PT2132188E/pt unknown
- 2008-03-06 AT AT08731517T patent/ATE537157T1/de active
- 2008-03-06 JP JP2009552883A patent/JP2010520307A/ja active Pending
- 2008-03-06 ES ES08731517T patent/ES2377165T3/es active Active
- 2008-03-06 CA CA002679965A patent/CA2679965A1/en not_active Abandoned
- 2008-03-06 WO PCT/US2008/056018 patent/WO2008109731A2/en not_active Ceased
- 2008-03-06 BR BRPI0808662A patent/BRPI0808662B8/pt not_active IP Right Cessation
- 2008-03-06 SI SI200830561T patent/SI2132188T1/sl unknown
- 2008-03-06 EA EA200970838A patent/EA200970838A1/ru unknown
- 2008-03-06 KR KR1020097020832A patent/KR20090118103A/ko not_active Withdrawn
- 2008-03-06 CL CL2008000669A patent/CL2008000669A1/es unknown
- 2008-03-06 HR HR20120160T patent/HRP20120160T1/hr unknown
- 2008-03-06 US US12/043,291 patent/US8119669B2/en not_active Expired - Fee Related
- 2008-03-06 RS RS20120106A patent/RS52247B/sr unknown
- 2008-03-06 TW TW097107936A patent/TW200902507A/zh unknown
- 2008-03-06 PL PL08731517T patent/PL2132188T3/pl unknown
- 2008-03-06 CN CN2008800153616A patent/CN101679326B/zh not_active Expired - Fee Related
- 2008-03-06 AU AU2008222749A patent/AU2008222749A1/en not_active Abandoned
- 2008-03-06 DK DK08731517.2T patent/DK2132188T3/da active
- 2008-03-07 AR ARP080100963A patent/AR065656A1/es not_active Application Discontinuation
-
2009
- 2009-09-06 IL IL200758A patent/IL200758A0/en unknown
- 2009-10-06 ZA ZA2009/06953A patent/ZA200906953B/en unknown
-
2012
- 2012-01-10 US US13/346,808 patent/US9034852B2/en not_active Expired - Fee Related
- 2012-03-07 CY CY20121100232T patent/CY1112778T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS52247B (sr) | 2012-10-31 |
| CY1112778T1 (el) | 2016-02-10 |
| DK2132188T3 (da) | 2012-02-27 |
| EP2132188B1 (en) | 2011-12-14 |
| BRPI0808662B1 (pt) | 2020-09-29 |
| TW200902507A (en) | 2009-01-16 |
| WO2008109731A3 (en) | 2008-11-27 |
| KR20090118103A (ko) | 2009-11-17 |
| PT2132188E (pt) | 2012-02-13 |
| ZA200906953B (en) | 2010-12-29 |
| CN101679326A (zh) | 2010-03-24 |
| IL200758A0 (en) | 2010-05-17 |
| EA200970838A1 (ru) | 2010-02-26 |
| SI2132188T1 (sl) | 2012-04-30 |
| US9034852B2 (en) | 2015-05-19 |
| ES2377165T3 (es) | 2012-03-23 |
| CA2679965A1 (en) | 2008-09-12 |
| ATE537157T1 (de) | 2011-12-15 |
| JP2010520307A (ja) | 2010-06-10 |
| NZ579418A (en) | 2012-01-12 |
| AU2008222749A1 (en) | 2008-09-12 |
| BRPI0808662B8 (pt) | 2021-05-25 |
| MX2009009519A (es) | 2009-11-18 |
| PL2132188T3 (pl) | 2012-05-31 |
| BRPI0808662A2 (pt) | 2014-08-26 |
| AR065656A1 (es) | 2009-06-24 |
| EP2132188A2 (en) | 2009-12-16 |
| US20080286265A1 (en) | 2008-11-20 |
| US8119669B2 (en) | 2012-02-21 |
| CN101679326B (zh) | 2012-12-12 |
| US20120108571A1 (en) | 2012-05-03 |
| WO2008109731A2 (en) | 2008-09-12 |
| HRP20120160T1 (hr) | 2012-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008000669A1 (es) | Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras. | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| CL2008000667A1 (es) | Compuestos derivados de fenoxi aminotiazolonas sustituidas, modulares de receptores alfa relacionados con estrogenos; composion farmaceutica que comprende a dichos compuestos; y sus uso para tratar cancer, sindrome metabolico, obesidad, diabetes. | |
| CL2008001815A1 (es) | Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
| CL2008002076A1 (es) | Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades. | |
| CL2008002521A1 (es) | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. | |
| CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
| UY30304A1 (es) | Moduladores de mglur5 i | |
| CL2011000544A1 (es) | Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades. | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| CL2008002538A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| CL2008002539A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
| CL2010001538A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular. | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| UY30308A1 (es) | Moduladores de mglur5 v | |
| CL2007002971A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
| CL2007002107A1 (es) | Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades. | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| CL2008003789A1 (es) | Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer. | |
| UY32464A (es) | Nuevos compuestos de indazol | |
| CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
| UY30307A1 (es) | Moduladores de mglur5 vi |